Literature DB >> 8812150

Microglial cell responses to fetal ventral mesencephalic tissue grafting and to active and adoptive immunizations.

M Shinoda1, J L Hudson, I Strömberg, B J Hoffer, J W Moorhead, L Olson.   

Abstract

Microglia express cytokines, major histocompatibility (MHC) loci, and several other immunologically important constituents. The aim of this study was to detect immunological responses of microglial cells following allogeneic dopaminergic transplantation using active and adoptive immunizations. Adult inbred Fisher 344 (F344 RT1) rats were unilaterally dopamine (DA) depleted in striatum by injection of 6-hydroxydopamine. The degree of degeneration was assessed by recording the rotational response to apomorphine. Fetal ventral mesencephalic tissue containing DA neuroblasts from Wistar-Furth (WF, RT1u) rat donors (9-12 mm CRL) were later implanted in striatum on the lesioned side. Lymph nodes and spleen cells were collected aseptically, resuspended, and diluted for isovolumetric injections. Animals selected for active immunization were injected intraperitoneally with varying amounts of WF lymphocytes. Animals selected for adoptive immunization (transferred immunity) were intraperitoneally injected with 10(8) F344 lymphocytes prepared from animals actively immunized 3 weeks previously. Monoclonal antibodies against CD4 (OX38), CD8 (OX8), CD11b (OX42), MHC class I (OX18), monomorphic MHC class II (OX-6), and ED1 and polyclonal antibodies against tyrosine hydroxylase (TH) were used for immunohistochemistry. We found that the degree of ED1-positive cell proliferation was well correlated to the immunization patterns. Groups that were actively immunized with or without prior adoptive immunization had a larger amount of reactive microglial proliferation. ED1 immunohistochemistry revealed patterns of immunolabeling of engrafted areas: 8-12 weeks after grafting in nonimmunized and adoptively immunized groups reactive microglial proliferation occurred only at the graft periphery. Active and adoptive + active immunization led to ED1-IR within the grafts themselves. At early stages nonimmunized groups had an ED1 pattern which was partially inside the grafts. At early time points nonimmunized groups contained ameboid microglial cells within the grafts which disappeared at later stages and were absent in the immunized groups. ED1-positive ameboid microglial cells within the grafts may be of graft origin and constitute a part of a continued normal development of the fetal tissue.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8812150     DOI: 10.1006/exnr.1996.0151

Source DB:  PubMed          Journal:  Exp Neurol        ISSN: 0014-4886            Impact factor:   5.330


  5 in total

Review 1.  Cell therapy in Parkinson's disease.

Authors:  Olle Lindvall; Anders Björklund
Journal:  NeuroRx       Date:  2004-10

Review 2.  The immunogenicity of midbrain dopaminergic neurons and the implications for neural grafting trials in Parkinson's disease.

Authors:  Shamma Qarin; Sarah K Howlett; Joanne L Jones; Roger A Barker
Journal:  Neuronal Signal       Date:  2021-09-13

3.  Hypoproliferative human neural progenitor cell xenografts survived extendedly in the brain of immunocompetent rats.

Authors:  Chunhua Liu; Xiaoyun Wang; Haitao Wang; Guangjin Pan; Xiaofen Zhong; Duanqing Pei; Yiping Guo; Wenhao Huang; Wei Meng; Zhenghui Su; Qi Xing; Heng Shi; Di Zhang; Min Zhou; Yifan Zhao
Journal:  Stem Cell Res Ther       Date:  2021-07-02       Impact factor: 6.832

4.  Cyclosporin promotes neurorestoration and cell replacement therapy in pre-clinical models of Parkinson's disease.

Authors:  Anna Tamburrino; Madeline J Churchill; Oi W Wan; Yolanda Colino-Sanguino; Rossana Ippolito; Sofie Bergstrand; Daniel A Wolf; Niculin J Herz; Michelle D Sconce; Anders Björklund; Charles K Meshul; Mickael Decressac
Journal:  Acta Neuropathol Commun       Date:  2015-12-14       Impact factor: 7.801

Review 5.  Glial cells in intracerebral transplantation for Parkinson's disease.

Authors:  Nikola Tomov
Journal:  Neural Regen Res       Date:  2020-07       Impact factor: 5.135

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.